Article
Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1-BCR-ABL-JAK2 complex.
Journal of the National Cancer Institute - 20 Mar 2013
Chen Min, Gallipoli Paolo, DeGeer Donna, Sloma Ivan, Forrest Donna L, Chan Matthew, Lai Damian, Jorgensen Heather, Ringrose Ashley, Wang Hui Mi, Lambie Karen, Nakamoto Helen, Saw Kyi Min, Turhan Ali, Arlinghaus Ralph, Paul James, Stobo Jon, Barnett Michael J, Eaves Allen, Eaves Connie J, Holyoake Tessa L, Jiang Xiaoyan
Abstract excerpt
BACKGROUND: Imatinib mesylate (IM) induces clinical remission of chronic myeloid leukemia (CML). The Abelson helper integration site 1 (AHI-1) oncoprotein interacts with BCR-ABL and Janus kinase 2 (JAK2) to mediate IM response of primitive CML cells, but the effect of the interaction complex on the response to ABL and JAK2 inhibitors is unknown. METHODS: The AHI-1-BCR-ABL-JAK2 interaction complex was analyzed by...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
